Among children with cystic fibrosis (CF), bone health tends to become worse with older age — and poor bone…
Marisa Wexler, MS
Marisa holds a Master of Science in cellular and molecular pathology from the University of Pittsburgh, where she studied novel genetic drivers of ovarian cancer. Her areas of expertise include cancer biology, immunology, and genetics, and she has worked as a science writing and communications intern for the Genetics Society of America.
At Bionews we’re committed to providing the most accurate, relevant, and up-to-date reporting for our patient communities. Our goal is to ensure that everyone has access to disease-specific information that is both trustworthy and easy to understand. You can read more about our editorial policy here.
Articles by Marisa Wexler, MS
Having cystic fibrosis (CF) can put a tremendous financial strain on patients: In the U.K., the typical family affected…
The Cystic Fibrosis Foundation is investing up to $15 million in ReCode Therapeutics to support the development of…
A novel inhaled antibiotic that Spexis is developing to treat infections of Pseudomonas aeruginosa — the key bacterial agent of lung…
The Phase 1b/2a clinical trial SWARM–Pa, testing Armata Pharmaceuticals‘ experimental phage therapy AP-PA02 in people with cystic fibrosis…
Claire’s Place Foundation has announced the launch of its fundraising campaign, called #CPFoneinamillion, to support families with…
People with cystic fibrosis (CF) who are treated with Orkambi and Symkevi (Symdeko) in real-world settings tend…
First Wave BioPharma has asked the U.S. Food and Drug Administration (FDA) for permission to start a Phase 2…
A novel gene-editing tool that allows scientists to “drag-and-drop” sequences of DNA into the genome, without inducing large cuts, could…
Vertex Pharmaceuticals recently filed an application with the U.S. Food and Drug Administration (FDA) asking that Trikafta, its…